Search results
Collagen
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome, storage pool disease) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Arachidonic Acid
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
ADP Assay for Platelet Aggregation
Investigation of congenital (e.g. Glanzmann’s thrombasthenia, Bernard-Soulier, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma, hepatic or renal failure). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDs and GPIIb/IIIa inhibitors.
Fibrinogen Fragment D, Human
For research use only.
Anti-sheep, donkey, IgG, affinity purified, biotinylated
Anti-sheep, donkey, IgG, affinity purified, FITC conjugated
BIOPHEN CS-01(38)
Chromogenic substrate for thrombin.
BIOPHEN Heparin LRT 3 (Liquid Reagent Technology)
Measuring the concentration of UFH, LMWH, Arixtra®, Orgaran®, rivaroxaban (Xarelto®), apixaban (Eliquis®) and edoxaban (Lixiana®) in patients’ plasma for monitoring the therapy and adjusting drug dosage.
BIOPHEN Heparin LRT 7.5 (Liquid Reagent Technology)
Measuring the concentration of UFH, LMWH, Arixtra®, Orgaran®, rivaroxaban (Xarelto®), apixaban (Eliquis®) and edoxaban (Lixiana®) in patients’ plasma for monitoring the therapy and adjusting drug dosage.
Thrombin (IIa), anti-human mouse, IgG